ICRI Mumbai Campus Announces Collaboration with Hinduja Hospital Mumbai for PG Diploma in Clinical Research, Pharmacovigilance, and Clinical Data Management

Mumbai  – ICRI, leaders in New Age Careers, proudly announce a groundbreaking partnership with Hinduja Hospital Mumbai, a renowned multi-specialty hospital at the forefront of medical innovation. This collaboration introduces a comprehensive Post Graduate Diploma in Clinical Research, Pharmacovigilance, and Clinical Data Management program, designed to equip aspiring professionals with the knowledge and skills essential to thrive in the dynamic field of clinical research.

This collaboration signifies a pivotal development in clinical research education in India. ICRI, recognized for delivering high-quality, career-oriented programs, and Hinduja Hospital Mumbai, known for its cutting-edge research facilities and esteemed team of professionals. The PG Diploma in Clinical Research, Pharmacovigilance, and Clinical Data Management program is meticulously designed to provide students with a thorough understanding of the entire clinical research process. Graduates of this program at ICRI Mumbai Campus will be well-positioned for successful careers in the ever-evolving field of clinical research.

Both ICRI and Hinduja Hospital Mumbai share a deep commitment to advancing clinical research through innovative research. This collaboration aims to cultivate a generation of well-equipped clinical research professionals who will contribute significantly to groundbreaking discoveries and advancements in medical science.

ICRI stands out as a premier institution, having been India’s first and most awarded institution in Clinical Research since 2004. With a network of over 19,000 alumni working globally, ICRI has earned 21 industry-specific awards, including the prestigious Presidential Award for contributions in Clinical Research, as well as recognitions from India Today, Star TV, ET Now, Higher Education Excellence Awards, and Saksham Education Award.

Kanishk Dugal, COO of ICRI, stated, “We are delighted to collaborate with a prestigious institution like Hinduja Hospital Mumbai. This partnership signifies our unwavering commitment to providing students with the best possible education and practical training opportunities in clinical research. This program will empower them to become valuable assets in the pursuit of new medical knowledge and treatments that will improve lives worldwide.”

ICRI’s programs ensure that graduates are academically equipped and professionally trained for the global job market. Notably, ICRI launched India’s first book on clinical research and pharmacovigilance, introduced the first PhD in Clinical Research, and organised the first international and national conference in clinical research. ICRI continues to prepare next-generation professionals in various fields including Clinical Research, Aviation & Logistics-Supply Chain, Psychology, Cyber Security, Data Sciences, and Agriculture through its unique university-hospital partnership model.

Dr. Sanjay Mehendale, Director of Research at P.D Hinduja Hospital Mumbai commented, “We are excited to partner with ICRI on this vital initiative. By sharing our expertise and resources, we aim to cultivate the next generation of clinical research professionals who will not only uphold the highest ethical standards but also contribute meaningfully to the development of life-saving treatments.”

The global clinical trials market size was estimated to exceed USD 50.0 billion in 2022 and is projected to reach USD 84.43 billion by 2030, registering a CAGR of 5.7% during the forecast period from 2022 to 2030. The COVID-19 pandemic underscored the importance of positioning India as a hub for clinical trials, with the country now among the top choices for global clinical trials due to its regulatory framework aligning with U.S. FDA norms.

India’s clinical trials market is expected to reach USD 3.15 billion by 2025, with a CAGR of 8.7%. The need for clinical research professionals is substantial, with approximately 50,000 positions currently required in the industry. The significant number of patients in India highlights the growing demand for treatments and immunizations, with 288 medicines and 106 vaccines in various development stages, including 7.0% in Phase IV, 21.0% in Phase III, and 43.0% and 13.0% in Phase II and Phase I respectively.